148 related articles for article (PubMed ID: 32921297)
1. The effects of cytochrome P450 2D6 inhibitors on a high-dose tramadol taper for medically supervised opioid withdrawal: a retrospective chart review.
Stump T; Cather J; Moore PS
J Addict Dis; 2021; 39(1):81-87. PubMed ID: 32921297
[No Abstract] [Full Text] [Related]
2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors.
Frost DA; Soric MM; Kaiser R; Neugebauer RE
Pharmacotherapy; 2019 Jun; 39(6):724-729. PubMed ID: 31038218
[TBL] [Abstract][Full Text] [Related]
4. A retrospective chart review of outcomes resulting from a three-day tramadol taper for acute opioid withdrawal.
Radcliff JA; Vellanki SC; Moore PS; Weisensell BJ; Cather JK
J Addict Dis; 2018; 37(3-4):252-258. PubMed ID: 31573412
[TBL] [Abstract][Full Text] [Related]
5. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
6. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
[TBL] [Abstract][Full Text] [Related]
8. Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study.
Tamaskar R; Parran TV; Heggi A; Brateanu A; Rabb M; Yu J
J Addict Dis; 2003; 22(4):5-12. PubMed ID: 14723474
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.
Arafa MH; Atteia HH
Toxicol Appl Pharmacol; 2018 May; 346():37-44. PubMed ID: 29555325
[TBL] [Abstract][Full Text] [Related]
10. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
12. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
13. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
Lofwall MR; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6*2 Polymorphism as a Predictor of Failed Outpatient Tramadol Therapy in Postherpetic Neuralgia Patients.
Nasare NV; Banerjee BD; Suryakantrao Deshmukh P; Mediratta PK; Saxena AK; Ahmed RS; Bhattacharya SN
Am J Ther; 2016; 23(3):e697-707. PubMed ID: 23567787
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.
Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K
Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129
[TBL] [Abstract][Full Text] [Related]
17. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.
Threlkeld M; Parran TV; Adelman CA; Grey SF; Yu J
Am J Addict; 2006; 15(2):186-91. PubMed ID: 16595358
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
19. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.
Dunn K; Bergeria C; Huhn AS; Strain EC
Drug Alcohol Depend; 2020 Oct; 215():108212. PubMed ID: 32781310
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.
Lofwall MR; Babalonis S; Nuzzo PA; Siegel A; Campbell C; Walsh SL
Drug Alcohol Depend; 2013 Nov; 133(1):188-97. PubMed ID: 23755929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
